MoringinCAS# 73255-40-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 73255-40-0 | SDF | Download SDF |
| PubChem ID | 153557 | Appearance | Powder |
| Formula | C14H17NO5S | M.Wt | 311.35 |
| Type of Compound | Phenols | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2S,3R,4R,5R,6S)-2-[4-(isothiocyanatomethyl)phenoxy]-6-methyloxane-3,4,5-triol | ||
| SMILES | CC1C(C(C(C(O1)OC2=CC=C(C=C2)CN=C=S)O)O)O | ||
| Standard InChIKey | QAZIHHJTZPNRCM-CNJBRALLSA-N | ||
| Standard InChI | InChI=1S/C14H17NO5S/c1-8-11(16)12(17)13(18)14(19-8)20-10-4-2-9(3-5-10)6-15-7-21/h2-5,8,11-14,16-18H,6H2,1H3/t8-,11-,12+,13+,14-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Moringin is a modulator of neuroinflammation via the β-catenin-PPARγ axis, it can activate Wnt canonical pathway by inhibiting GSK3β in a mouse model of experimental autoimmune encephalomyelitis. 2. The combination of cannabidiol and moringin has anti-inflammatory, antioxidative, and anti-apoptotic effects. 3. Moringin is effective in inducing apoptosis through p53 and Bax activation and Bcl-2 inhibition, it demonstrates the antitumor efficacy in human malignant astrocytoma cells. |
| Targets | PPAR | GSK-3 | COX | IL Receptor | gp120/CD4 | Nrf2 | Wnt/β-catenin | TNF-α | Bcl-2/Bax | Caspase | p53 |
Moringin Dilution Calculator
Moringin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.2118 mL | 16.0591 mL | 32.1182 mL | 64.2364 mL | 80.2955 mL |
| 5 mM | 0.6424 mL | 3.2118 mL | 6.4236 mL | 12.8473 mL | 16.0591 mL |
| 10 mM | 0.3212 mL | 1.6059 mL | 3.2118 mL | 6.4236 mL | 8.0295 mL |
| 50 mM | 0.0642 mL | 0.3212 mL | 0.6424 mL | 1.2847 mL | 1.6059 mL |
| 100 mM | 0.0321 mL | 0.1606 mL | 0.3212 mL | 0.6424 mL | 0.803 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Methylnaltrexone Bromide
Catalog No.:BCC1740
CAS No.:73232-52-7
- Florfenicol
Catalog No.:BCC8984
CAS No.:73231-34-2
- ITF2357 (Givinostat)
Catalog No.:BCC2150
CAS No.:732302-99-7
- Remoxipride hydrochloride
Catalog No.:BCC6844
CAS No.:73220-03-8
- Chloranthalactone E
Catalog No.:BCN7466
CAS No.:73215-92-6
- Xamoterol hemifumarate
Catalog No.:BCC6861
CAS No.:73210-73-8
- Baptifoline
Catalog No.:BCN7988
CAS No.:732-50-3
- (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin
Catalog No.:BCC6011
CAS No.:73168-24-8
- Effusol
Catalog No.:BCN2928
CAS No.:73166-28-6
- Fenticonazole nitrate
Catalog No.:BCC8983
CAS No.:73151-29-8
- Ferruginine
Catalog No.:BCN1911
CAS No.:73069-63-3
- Arecoline
Catalog No.:BCN8537
CAS No.:73069-28-9
- 5-O-Caffeoylshikimic acid
Catalog No.:BCN7929
CAS No.:73263-62-4
- 1,4-Dihydro-1,2-dimethyl-4-oxo-3-quinolinecarboxylic acid
Catalog No.:BCN1369
CAS No.:73281-83-1
- Deoxynojirimycin hydrochloride
Catalog No.:BCN2626
CAS No.:73285-50-4
- BAY 61-3606
Catalog No.:BCC1406
CAS No.:732983-37-8
- Methylnissolin
Catalog No.:BCN1368
CAS No.:733-40-4
- 3-Hydroxy-9,10-Dimethoxypterocarpan
Catalog No.:BCC8101
CAS No.:73340-41-7
- Macbecin I
Catalog No.:BCC7551
CAS No.:73341-72-7
- Albanin A
Catalog No.:BCN3290
CAS No.:73343-42-7
- 9-O-Acetyl-4,4'-di-O-methyllariciresinol
Catalog No.:BCN1367
CAS No.:73354-15-1
- Niclosamide monohydrate
Catalog No.:BCC5212
CAS No.:73360-56-2
- SCH 50911
Catalog No.:BCC5692
CAS No.:733717-87-8
- SB 706375
Catalog No.:BCC6256
CAS No.:733734-61-7
Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages.[Pubmed:27215129]
Fitoterapia. 2016 Jul;112:104-15.
Inflammatory response plays an important role in the activation and progress of many debilitating diseases. Natural products, like cannabidiol, a constituent of Cannabis sativa, and Moringin, an isothiocyanate obtained from myrosinase-mediated hydrolysis of the glucosinolate precursor glucoMoringin present in Moringa oleifera seeds, are well known antioxidants also endowed with anti-inflammatory activity. This is due to a covalent-based mechanism for ITC, while non-covalent interactions underlie the activity of CBD. Since these two mechanisms are distinct, and the molecular endpoints are potentially complementary, we investigated in a comparative way the protective effect of these compounds alone or in combination on lipopolysaccharide-stimulated murine macrophages. Our results show that the cannabidiol (5muM) and Moringin (5muM) combination outperformed the single constituents that, at this dosage had only a moderate efficacy on inflammatory (Tumor necrosis factor-alpha, Interleukin-10) and oxidative markers (inducible nitric oxide synthase, nuclear factor erythroid 2-related factor 2, nitrotyrosine). Significant upregulation of Bcl-2 and downregulation of Bax and cleaved caspase-3 was observed in cells treated with cannabidiol-Moringin combination. Treatment with the transient receptor potential vanilloid receptor 1 antagonist was detrimental for the efficacy of cannabidiol, while no effect was elicited by cannabinoid receptor 1 and cannabinoid receptor 2 antagonists. None of these receptors was involved in the activity of Moringin. Taken together, our in vitro results testify the anti-inflammatory, antioxidative, and anti-apoptotic effects of the combination of cannabidiol and Moringin.
Moringin activates Wnt canonical pathway by inhibiting GSK3beta in a mouse model of experimental autoimmune encephalomyelitis.[Pubmed:27784989]
Drug Des Devel Ther. 2016 Oct 4;10:3291-3304.
Aberrant canonical Wnt-beta-catenin signaling has been reported in multiple sclerosis (MS), although the results are controversial. The present study aimed to examine the role of the Wnt-beta-catenin pathway in experimental MS and also to test Moringin (4-[alpha-L-rhamnopyranosyloxy]-benzyl isothiocyanate), resulting from exogenous myrosinase hydrolysis of the natural phytochemical glucoMoringin 4(alpha-L-rhamnosyloxy)-benzyl glucosinolate as a modulator of neuroinflammation via the beta-catenin-PPARgamma axis. Experimental autoimmune encephalomyelitis (EAE), the most common model of MS, was induced in C57BL/6 mice by immunization with MOG35-55. Released Moringin (10 mg/kg glucoMoringin +5 muL myrosinase/mouse) was administered daily for 1 week before EAE induction and continued until mice were killed on day 28 after EAE induction. Our results clearly showed that the Wnt-beta-catenin pathway was downregulated in the EAE model, whereas Moringin pretreatment was able to avert this. Moringin pretreatment normalizes the aberrant Wnt-beta-catenin pathway, resulting in GSK3beta inhibition and beta-catenin upregulation, which regulates T-cell activation (CD4 and FoxP3), suppresses the main inflammatory mediators (IL-1beta, IL-6, and COX2), through activation of PPARgamma. In addition, Moringin attenuates apoptosis by reducing the expression of the Fas ligand and cleaved caspase 9, and in parallel increases antioxidant Nrf2 expression in EAE mice. Taken together, our results provide an interesting discovery in identifying Moringin as a modulator of the Wnt-beta-catenin signaling cascade and as a new potential therapeutic target for MS treatment.
Anticancer activity of glucomoringin isothiocyanate in human malignant astrocytoma cells.[Pubmed:26882972]
Fitoterapia. 2016 Apr;110:1-7.
Isothiocyanates (ITCs) released from their glucosinolate precursors have been shown to inhibit tumorigenesis and they have received significant attention as potential chemotherapeutic agents against cancer. Astrocytoma grade IV is the most frequent and most malignant primary brain tumor in adults without any curative treatment. New therapeutic drugs are therefore urgently required. In the present study, we investigated the in vitro antitumor activity of the glycosylated isothiocyanate Moringin [4-(alpha-l-rhamnopyranosyloxy)benzyl isothiocyanate] produced from quantitative myrosinase-induced hydrolysis of glucoMoringin (GMG) under neutral pH value. We have evaluated the potency of Moringin on apoptosis induction and cell death in human astrocytoma grade IV CCF-STTG1 cells. Moringin showed to be effective in inducing apoptosis through p53 and Bax activation and Bcl-2 inhibition. In addition, oxidative stress related Nrf2 transcription factor and its upstream regulator CK2 alpha expressions were modulated at higher doses, which indicated the involvement of oxidative stress-mediated apoptosis induced by Moringin. Moreover, significant reduction in 5S rRNA was noticed with Moringin treatment. Our in vitro results demonstrated the antitumor efficacy of Moringin derived from myrosinase-hydrolysis of GMG in human malignant astrocytoma cells.
